IMVT Shares Drop 2.4% After Batoclimab Fails to Meet Key Goals in Final-Stage Trial
Immunovant's batoclimab failed to meet its primary efficacy goals in two late-stage clinical trials for thyroid eye disease, causing the company's stock to drop by 2.4%. Despite the setback in efficacy, the drug's safety profile remained consistent with previous studies. Immunovant plans to discuss the future of batoclimab with HanAll Biopharma and continues to focus on developing another FcRn inhibitor, IMVT-1402.
Immunovant Inc stock: Why biotech investors are watching this closely now
Immunovant Inc is a clinical-stage biopharma company focused on developing antibody therapies for autoimmune diseases, particularly targeting the neonatal Fc receptor (FcRn) to reduce harmful autoantibodies. Its lead candidate, batoclimab, is undergoing Phase 3 trials for thyroid eye disease and myasthenia gravis, with anotherFcRn inhibitor, IMVT-1402, in development. The company's pipeline and strategic focus on precision medicine in the growing autoimmune market are attracting investor attention, despite the inherent risks of biotech investing.
Immunovant Inc stock: Why biotech investors are watching this closely now
Immunovant Inc is a clinical-stage biopharmaceutical company focused on developing antibody therapies for autoimmune diseases, particularly targeting conditions like thyroid eye disease and myasthenia gravis with its lead candidate, batoclimab. The company's innovative approach involves inhibiting the neonatal Fc receptor (FcRn) to reduce harmful autoantibodies, positioning it as a significant player in the growing global autoimmune market. With multiple programs in mid-stage trials and positive analyst sentiment, Immunovant presents a high-growth opportunity for investors attuned to developments in precision medicine, despite the inherent risks of biotech investing.
Aberdeen Group plc Increases Stake in Immunovant, Inc. $IMVT
Aberdeen Group plc increased its stake in Immunovant, Inc. by 20.6% in the fourth quarter of 2025, now owning 1,184,122 shares valued at approximately $30.1 million. This increase occurred despite setbacks for Immunovant, including the failure of its drug batoclimab in Phase 3 trials and insider selling by CEO Eric Venker. Analysts maintain a "Hold" consensus rating with a target price of $32.00, while the company focuses on its brepocitinib program to mitigate losses from the batoclimab failure.
Immunovant falls on late-stage trial setback for TED therapy
The article reports that Immunovant's stock fell due to a late-stage trial setback for its Thyroid Eye Disease (TED) therapy. This indicates a negative outcome in the clinical development of their treatment, likely impacting investor confidence and the company's market valuation.
Immunovant (NASDAQ:IMVT) CEO Sells $342,918.90 in Stock
Immunovant CEO Eric Venker sold 14,229 shares of the company's stock for $342,918.90, reducing his ownership by over 42% following the failure of their Batoclimab drug in Phase 3 trials. This sale, coupled with the clinical setback, has introduced negative sentiment, although the company is shifting its research and development focus to a new asset, brepocitinib. The stock currently has an average "Hold" rating from analysts with a consensus price target of $32.00.
Immunovant (IMVT) CEO Venker sells $342,854 in shares
Immunovant CEO Eric Venker sold $342,854 in company shares on April 2, 2026, stemming from tax withholding obligations related to the vesting of Capped Value Appreciation Rights. These transactions occurred amidst recent setbacks in Immunovant's Phase 3 clinical trials for batoclimab, leading to mixed reactions from analysts regarding the company's future prospects. Despite the trial failures, analysts are also focusing on the potential of Immunovant’s next-generation drug, IMVT-1402.
Immunovant (IMVT) CEO settles CVARs into 368,750 shares, disposes stock
Immunovant (IMVT) CEO Eric Venker converted 368,750 Capped Value Appreciation Rights (CVARs) into common stock on April 1, 2026, based on a $14.46 hurdle price. He then disposed of 334,960 shares to the issuer and sold an additional 14,229 shares in non-discretionary "sell to cover" transactions to satisfy tax obligations. Following these transactions, Venker directly holds 19,561 shares of Immunovant.
Immunovant (IMVT) CEO Venker sells $342,854 in shares
Immunovant (IMVT) CEO Eric Venker sold $342,854 worth of company stock through two transactions on April 2, 2026, after exercising Capped Value Appreciation Rights (CVARs) on April 1, 2026. The sales were made to cover tax withholding obligations related to the vesting and settlement of these CVARs. The article also notes recent mixed analyst reactions to Immunovant's Phase 3 clinical trial failures for batoclimab, while maintaining focus on next-generation drug IMVT-1402.
IMVT: Brepocitinib advances into pivotal LPP trials as batoclimab's TED study informs Graves' strategy
Immunovant (IMVT) is moving its drug brepocitinib into pivotal trials for lichen planopilaris (LPP), a high unmet need indication, due to its JAK1/TYK2 mechanism. Although the phase III study for batoclimab in thyroid eye disease (TED) did not meet its primary endpoint, the data collected will be used to guide the development strategy for IMVT-1402 in Graves' disease. The article highlights these key developments for Immunovant's drug pipeline.
Leerink cuts Immunovant stock price target on failed TED trial
Leerink Partners lowered its price target on Immunovant Inc. (NASDAQ:IMVT) to $50 from $52, maintaining an Outperform rating, after the company's batoclimab failed to meet the primary endpoint in Phase 3 trials for thyroid eye disease. Despite this setback, the firm sees limited downside due to low investor expectations and focuses on Immunovant’s next-generation FcRn inhibitor IMVT-1402, which has several potential value-inflecting readouts anticipated in the coming months for other autoimmune diseases. Other analysts also acknowledge the setback but maintain positive outlooks for IMVT-1402, highlighting the company's financial flexibility.
Alto Neuroscience, Immunovant And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were down on Thursday, with several companies experiencing significant drops in pre-market trading. Alto Neuroscience shares fell 13.6% after its Phase 2 clinical trial did not meet statistical significance. Immunovant Inc. also saw an 8.3% decline following the announcement of its Phase 3 study results.
Immunovant falls on late-stage trial setback (IMVT:NASDAQ)
Immunovant (IMVT) shares dropped significantly in premarket trading following the announcement of a setback in a late-stage clinical trial for batoclimab, its experimental therapy for thyroid eye disease. The company, a subsidiary of Roivant Sciences (ROIV), reported the failure of the program. This news led to a ~10% decline in Immunovant's stock value.
Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
Immunovant announced that its two Phase 3 clinical studies for batoclimab in treating moderate-to-severe thyroid eye disease (TED) failed to meet their primary endpoint. While safety results were consistent with previous findings, the treatment did not achieve the desired proptosis responder rate. The company plans to focus on its investigational FcRn blocker IMVT-1402 for other autoimmune diseases, with Graves’ disease as a key priority, and expects data in 2027.
Two late-stage thyroid eye disease trials miss for Immunovant
Immunovant announced that its two Phase 3 clinical studies for batoclimab in active, moderate-to-severe thyroid eye disease (TED) failed to meet their primary endpoint. Despite this, safety results were consistent with previous findings, and patients showed greater proptosis improvement during the high-dose period. The company will review batoclimab's future plans with its partner HanAll and remains focused on advancing IMVT-1402 for other autoimmune diseases, with Graves’ disease topline data expected in 2027.
Hennion & Walsh Asset Management Inc. Makes New Investment in Immunovant, Inc. $IMVT
Hennion & Walsh Asset Management Inc. has acquired a new stake of 71,705 shares, valued at approximately $1.823 million, in Immunovant, Inc. during the fourth quarter. This move is part of broader institutional investment, with several other hedge funds also increasing their positions, bringing the total institutional ownership to 47.08%. Immunovant reported strong Q4 EPS, beating estimates, and currently holds a "Hold" consensus rating from analysts with an average target price of $32.00.
Sjögren’s Syndrome Market Poised for Significant Expansion Through 2034, Driven by Advancing Pipeline Therapies and Rising Disease Burden | DelveInsight Analysis Featuring Astellas Pharma, Immunovant
The Sjögren’s syndrome market is projected for significant growth through 2034, driven by an expanding patient population, increased awareness, and a robust pipeline of emerging therapies. Key players like Astellas Pharma, Immunovant, Novartis AG, and Johnson & Johnson are advancing innovative treatments such as biologics and targeted therapies. The market, valued at approximately USD 1.9 billion in 2023 across the seven major markets, is expected to grow steadily, with the U.S. accounting for the largest share of diagnosed cases.
Responsive Playbooks and the IMVT Inflection
This article analyzes Immunovant Inc. (NASDAQ: IMVT) through AI-generated signals, indicating positive near-term sentiment with a weak mid-term bias within a long-term strength context. It provides institutional trading strategies for various risk profiles, including long, momentum breakout, and short positions, along with multi-timeframe signal analysis. The analysis also highlights elevated downside risk and offers real-time trading signals and personalized alerts for subscribers.
LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT
LifeSci Capital has reiterated its Buy rating on Immunovant (IMVT) and maintained a price target of $50. This decision reflects the firm's continued positive outlook on the biopharmaceutical company.
LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT
LifeSci Capital has reiterated its Buy rating on Immunovant (IMVT) with a $50 price target. This continued positive outlook suggests the firm sees strong potential in the pharmaceutical company. Investors will likely watch Immunovant's stock performance closely following this analyst endorsement.
Immunovant (NASDAQ:IMVT) Insider Tuyl Christopher Van Sells 2,877 Shares
Immunovant (NASDAQ:IMVT) Director Tuyl Christopher Van sold 2,877 shares of the company's stock for $71,838.69 on March 18, 2026, reducing his stake by 1.92%. Despite beating quarterly EPS estimates, the stock's performance and fundamentals show mixed signals, with a "Hold" consensus rating from analysts and a target price of $32. Institutional investors have also adjusted their holdings in the company.
Immunovant (IMVT): Chief legal officer Van Tuyl sells $71k in stock By Investing.com
Immunovant's Chief Legal Officer, Christopher Van Tuyl, sold 2,877 shares of common stock for $71,838 to cover tax obligations related to restricted stock unit vesting. The stock is currently trading at $22.99, down from the transaction price but up 60% over six months. Immunovant recently exceeded Q3 2026 earnings expectations and received a "neutral" rating from Bernstein SocGen Group with a $28.00 price target.
Immunovant (IMVT): Chief legal officer Van Tuyl sells $71k in stock
Immunovant's Chief Legal Officer, Christopher Van Tuyl, sold 2,877 shares of common stock for $71,838 to cover tax obligations from RSU vesting. This transaction occurred on March 18, 2026, with shares trading at $24.97 at the time of sale. Despite the sale, Van Tuyl still directly owns 147,053 shares, and the company recently reported better-than-expected Q3 2026 earnings and received new analyst coverage.
Immunovant, Inc. (IMVT) CLO sells 2,877 shares to cover RSU taxes
Immunovant, Inc.'s Chief Legal Officer, Christopher Van Tuyl, sold 2,877 shares of common stock at $24.97 per share. This transaction on March 18, 2026, was mandated to cover tax withholding obligations from recently vested restricted stock units, not a discretionary trade. After the sale, Van Tuyl directly holds 147,053 shares.
Bernstein initiates Immunovant stock coverage with neutral rating
Bernstein SocGen Group has initiated coverage on Immunovant Inc. (NASDAQ:IMVT) with a "Market Perform" rating and a $28.00 price target. The firm values Immunovant's Graves' disease program at $2.4 billion and its Sjogren's syndrome program at $2.0 billion on a non-risk-adjusted basis. This follows Immunovant's recent report of third-quarter 2026 earnings per share that exceeded analyst expectations.
Understanding the Setup: (IMVT) and Scalable Risk
This article analyzes Immunovant Inc. (NASDAQ: IMVT), highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents three AI-generated trading strategies with specific entry, target, and stop-loss levels, emphasizing a significant 47.4:1 risk-reward setup targeting a 14.3% gain against 0.3% risk. The analysis suggests that while support is being tested, if it holds, resistance is the next expected movement.
Bernstein initiates Immunovant stock coverage with neutral rating
Bernstein SocGen Group has initiated coverage on Immunovant Inc. (NASDAQ:IMVT) with a Market Perform rating and a price target of $28.00. The firm values Immunovant's Graves' disease and Sjogren's syndrome programs at $2.4 billion and $2.0 billion respectively on a non-risk-adjusted basis. Immunovant recently reported Q3 2026 earnings per share of -0.61, surpassing analyst expectations of -0.72.
Immunovant, Inc. $IMVT is Alpine Global Management LLC's 3rd Largest Position
Alpine Global Management LLC has increased its holdings in Immunovant, Inc. (NASDAQ:IMVT) by 4.9%, making it their third-largest position, valued at $44.4 million. Other institutional investors like Deep Track Capital LP, Armistice Capital LLC, Two Seas Capital LP, and ADAR1 Capital Management LLC have also significantly boosted their stakes in Immunovant. The stock has a market cap of $5.11 billion and a consensus "Moderate Buy" rating from analysts with an average target price of $32.50.
Immunovant, Inc. $IMVT Shares Purchased by Granahan Investment Management LLC
Granahan Investment Management LLC increased its stake in Immunovant, Inc. (NASDAQ:IMVT) by 24.9% in the third quarter, bringing its total holdings to 266,221 shares valued at $4.29 million. Several other institutional investors also adjusted their positions in the company, with hedge funds and institutional investors collectively owning 47.08% of the stock. Insider selling was also noted, with two insiders selling a total of 13,993 shares for approximately $374,355.
Prosight Management LP Has $11.26 Million Stock Position in Immunovant, Inc. $IMVT
Prosight Management LP significantly increased its stake in Immunovant, Inc. by 45.7%, now holding 698,472 shares valued at $11.26 million, making it their 18th largest holding. Institutional investors collectively own 47.08% of Immunovant, while insiders have sold a total of 13,993 shares recently. Analysts maintain a "Moderate Buy" rating with an average target price of $32.50, and the company recently beat EPS estimates.
Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish
Alpine Global Management reduced its stake in Immunovant (NASDAQ:IMVT) by 127,039 shares, valued at $2.83 million, during the fourth quarter of 2025. Despite this trim, Immunovant remains the largest holding in Alpine's portfolio, accounting for over 11% of its assets, indicating continued conviction. The article suggests this sale was likely a rebalancing effort after a strong stock performance, as Immunovant progresses its lead asset, batoclimab, through Phase 3 clinical trials for autoimmune diseases.
Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish
Alpine Global Management recently trimmed its stake in Immunovant by selling 127,039 shares, valued at approximately $2.83 million, in the fourth quarter of 2025. Despite this sale, Immunovant remains the largest holding in Alpine's portfolio, accounting for over 11% of its assets, suggesting continued conviction. The article indicates that this reduction might be a rebalancing effort after a strong stock performance, as Immunovant continues to advance its clinical-stage drug candidates for autoimmune diseases, with key Phase 3 data expected in the first half of the year.
The Technical Signals Behind (IMVT) That Institutions Follow
This article provides a technical analysis of Immunovant Inc. (NASDAQ: IMVT) based on AI models from Stock Traders Daily. It highlights a weak near-term sentiment but strong mid and long-term outlooks, identifying key support and resistance levels. The analysis offers specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry points, targets, and stop losses for different risk profiles.
Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 Earnings Update
Following its Q3 2025 earnings report, Immunovant, Inc. (NASDAQ:IMVT) saw multiple analysts raise their price targets. The company reported a narrower-than-expected loss of -$0.61 per share and provided updates on upcoming trial data for its treatments for rheumatoid arthritis, cutaneous lupus erythematosus, and thyroid eye disease. Analysts like Guggenheim's Yatin Suneja and Truist's Danielle Brill adjusted their price targets upwards, with the former raising his to $44 and the latter to $23.
Immunovant Stock Surges 17% in 3 Months: What's Driving It?
Immunovant's stock has surged 17% in the last three months, fueled by positive investor sentiment regarding its pipeline advancements and strong financial health. The company is progressing with its lead candidate, IMVT-1402, for various autoimmune diseases, with key data expected in 2026 and 2027. Additionally, a recent financing round boosted its cash reserves, securing its operational funding through the potential commercial launch of IMVT-1402 for Graves’ disease.
Citigroup Inc. Sells 75,860 Shares of Immunovant, Inc. $IMVT
Citigroup Inc. reduced its stake in Immunovant, Inc. (NASDAQ:IMVT) by 23.9%, selling 75,860 shares and ending the recent quarter with 242,022 shares valued at approximately $3.9 million. Despite this, other hedge funds increased their positions, and institutional ownership stands at nearly 47.1%. Immunovant's stock is trading near $27 with a market capitalization of $5.51 billion, and analysts have a "Moderate Buy" rating with a target price of $32.50.
Immunovant Stock Surges 17% in 3 Months: What's Driving It?
Immunovant (IMVT) stock has surged 17% in the past three months and 40% over the past year, driven by strong pipeline progress and a robust financial position. The company is advancing its lead candidate, IMVT-1402, for various autoimmune conditions, with key data readouts expected in 2026 and 2027, and also evaluating batoclimab. A recent $550 million financing has bolstered its cash reserves, extending its runway through the potential commercial launch of IMVT-1402 for Graves' disease.
Vanguard Group Inc. Has $110.05 Million Holdings in Immunovant, Inc. $IMVT
Vanguard Group Inc. reduced its stake in Immunovant (IMVT) by 2.8% in Q3, now holding 6,826,810 shares valued at $110.05 million. Despite this, other institutional investors increased their positions, and analysts maintain a "Moderate Buy" rating with an average price target of $32.50. Immunovant recently beat earnings estimates, though insiders have sold shares totaling over $374,000 in the past 90 days.
TD Asset Management Inc Sells 56,752 Shares of Immunovant, Inc. $IMVT
TD Asset Management Inc. reduced its stake in Immunovant, Inc. by 29.5% in the third quarter, selling 56,752 shares and retaining 135,754 shares valued at $2.19 million. Immunovant shares currently trade at $27.08 with a market capitalization of $5.51 billion and recently reported an EPS of ($0.61), beating estimates. Analysts have a "Moderate Buy" consensus rating with an average price target of $32.50.
How Investors Are Reacting To Immunovant (IMVT) Narrower Q3 Loss and 2026 Autoimmune Trial Milestones
Immunovant (IMVT) reported a narrower-than-expected Q3 loss and confirmed 2026 milestones for its autoimmune clinical programs, including proof-of-concept studies and Phase 3 trials for batoclimab. Despite the improved financial results, the market's reaction suggests a focus remains on clinical data risks and the execution of its growing autoimmune antibody pipeline, rather than only the Q3 beat. The company's investment narrative is heavily reliant on the success of these trials and continued funding, with its share price potentially overvalued according to some analyses.
How Investors Are Reacting To Immunovant (IMVT) Narrower Q3 Loss and 2026 Autoimmune Trial Milestones
Immunovant (IMVT) reported a narrower-than-expected Q3 loss and announced key autoimmune clinical trial milestones for 2026, including proof-of-concept studies and Phase 3 trials. Investors are primarily focused on the 2026 readouts from its autoimmune antibody pipeline rather than recent earnings, with the stock experiencing a 7-day share price pullback. Despite improved confidence, concerns about funding needs, dilution risk, and the company's valuation remain central to the investment narrative.
Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 Earnings Update
Immunovant, Inc. (IMVT) reported Q3 2025 results with a smaller-than-anticipated loss per share, beating consensus estimates. The company anticipates key data releases in the latter half of 2026 and the first half of this year from various clinical trials. Following these results, several analysts reiterated their ratings but raised price targets for IMVT.
Immunovant (IMVT) COO executes 3,238-share sell-to-cover tax transaction
Immunovant, Inc.'s Chief Operating Officer, Gloria Melanie, reported three open-market sales totaling 3,238 shares of common stock on February 25, 2026. These transactions were executed to cover tax withholding obligations associated with the vesting of 6,872 restricted stock units and were mandated as "sell to cover" arrangements, not discretionary trading decisions. Following these sales, Melanie Gloria benefically owns 170,273 shares.
Precision Trading with Immunovant Inc. (IMVT) Risk Zones
This article analyzes Immunovant Inc. (IMVT) with AI models, highlighting a strong sentiment across all horizons and an exceptional 58.7:1 risk-reward setup. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, with specific entry, target, and stop-loss zones. The analysis also provides multi-timeframe signal support and resistance levels for near-term, mid-term, and long-term horizons.
IMVT Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Immunovant Inc (IMVT), including its income statement, balance sheet, and cash flow statement. It highlights the company's financial health, key metrics for fiscal year 2025 such as negative net income and free cash flow, and outlines metrics like R&D spending, cash and debt levels, and shares outstanding. The report also addresses common questions about IMVT's profitability, EPS, and cash runway, indicating weak financial health based on its Piotroski F-Score and low earnings quality.
Aberdeen Group plc Has $15.83 Million Stock Position in Immunovant, Inc. $IMVT
Aberdeen Group plc significantly increased its stake in Immunovant, Inc. (NASDAQ:IMVT) by 16.2% in the third quarter, bringing its total holdings to 981,804 shares valued at approximately $15.83 million. Immunovant shares opened at $26.65, trading within a 52-week range of $12.72–$27.92, and the company has a market cap of $5.42 billion. Analyst sentiment for IMVT is generally favorable, with a "Moderate Buy" consensus and an average price target of $31.11, despite some recent insider selling.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
Purcell & Lefkowitz LLP has announced a shareholder investigation into Immunovant, Inc. (NASDAQ: IMVT). The firm is looking into whether the company's directors breached their fiduciary duties through recent corporate actions. Shareholders of Immunovant, Inc. are encouraged to contact Purcell & Lefkowitz LLP for information regarding their rights and options.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
Purcell & Lefkowitz LLP has initiated a shareholder investigation into Immunovant, Inc. (NASDAQ: IMVT). The firm is looking into whether Immunovant's directors breached their fiduciary duties through recent corporate actions. Shareholders of Immunovant are encouraged to contact the law firm for more information regarding their rights and options.
Immunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of "Moderate Buy" from Analysts
Immunovant, Inc. (NASDAQ:IMVT) has an average "Moderate Buy" rating from analysts, with a consensus 12-month price target of $31.11. The company recently reported Q3 EPS of ($0.61), beating estimates, and analysts project ($2.69) EPS for the current year. Insider selling occurred last quarter, but institutions hold a significant portion of the stock.
Technical Reactions to IMVT Trends in Macro Strategies
This article analyzes Immunovant Inc. (NASDAQ: IMVT) using AI models to provide technical reactions and trading strategies. It highlights a near-term strong sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward setup. Three distinct trading strategies are offered for different risk profiles, along with multi-timeframe signal analysis.
